Back to Search
ROBERT AMATO, DMD
DMD
Endodontics
NPI: 1922169267Individual
Specialties, Licenses & Credentials
EndodonticsPrimary
Dentist — Endodontics
Code: 1223E0200X
14451(MA)
Research & Publications (20)
Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial.
PMID 19561532·J Immunother·2009
3-trial
A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
PMID 19306412·Cancer·2009
3-trial
A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
PMID 17701037·Cancer Chemother Pharmacol·2008
3-trial
Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial.
PMID 19010868·Clin Cancer Res·2008
3-trial
Pilot study of rapamycin in patients with hormone-refractory prostate cancer.
PMID 18824432·Clin Genitourin Cancer·2008
8-other
Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results.
PMID 18824428·Clin Genitourin Cancer·2008
3-trial
Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
PMID 18525301·Am J Clin Oncol·2008
3-trial
Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer.
PMID 18472641·J Exp Ther Oncol·2008
3-trial
Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial.
PMID 18418219·Anticancer Drugs·2008
3-trial
Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
PMID 19060583·Am J Clin Oncol·2008
3-trial
Current immunotherapeutic strategies in renal cell carcinoma.
PMID 18022554·Surg Oncol Clin N Am·2007
6-review
Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy.
PMID 18272023·Clin Genitourin Cancer·2007
6-review
5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy.
PMID 17727334·Expert Opin Biol Ther·2007
6-review
Heat-shock protein-peptide complex-96 for the treatment of cancer.
PMID 17696824·Expert Opin Biol Ther·2007
6-review
IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cells.
PMID 17571248·J Mol Med (Berl)·2007
8-other
A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
PMID 16729912·Clin Genitourin Cancer·2006
3-trial
Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
PMID 16475152·Cancer·2006
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
4.9(697)
- Address
- 1 WASHINGTON ST, SUITE 103
WELLESLEY, MA 02481 - Phone
- (781) 235-5700
- Website
- limitedtoendodontics.com
4.9(697)
See full reviewsQuick Facts
- NPI
- 1922169267
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile